Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.

Abstract: The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.

Abstract: The present invention relates to an immunogenic composition comprising first and second RNA replicon particles. The first RNA replicon particle comprises a nucleic acid construct comprising first and second nucleic acid sequences encoding first and second hemagglutinin (HA) antigens of a Swine influenza A virus (IAV-S). The first HA antigen is a of the A/swine/Gent/1/1984-like H3N2 (Gent/84) lineage, and the second HA antigen is of the A(H1N1)pdm09 (pdm09) lineage. The second RNA replicon particle comprises a nucleic acid construct comprising third and fourth nucleic acid sequences encoding third and fourth HA antigens of S. The third HA antigen is of the A/swine/Scotland/410440/1994-like H1huN2 (Scot/94) lineage, and the fourth HA antigen is of the Eurasian avian-like H1avN1 (EA) lineage. In other embodiments, the present invention relates to a vaccine, which may be used against influenza A virus infection, and comprising the immunogenic composition.

Abstract: The present invention relates to a nucleic acid construct that encodes, in this order, a first Swine influenza A (IAV-S) hemagglutinin (HA) antigen of the Scot/94 lineage and a second Swine influenza A (IAV-S) hemagglutinin (HA) antigen of the Eurasian avian-like (EA) lineage, and a nucleic acid construct that encodes, in this order, a first IAV-S HA antigen of the Gent/84 lineage and a second IAV-S HA antigen of pandemic09 (pdm09) lineage. In other embodiments, the present invention relates to RNA replicon particles comprising one or both nucleic acid constructs, an immunogenic composition, such as a vaccine, which may be used against influenza A virus infections, and comprising the replicon particles. Further provided are methods of making the vaccine and use of the vaccine.

Abstract: The present invention relates to a nucleic acid construct comprising first, second and third nucleic acid sequences encoding first, second and third neuraminidase (NA) antigens of a Swine influenza A virus (IAV-S). The first NA antigen is of the A/swine/Scotland/410440/1994-like H1huN2 (Scot/94) lineage, the second NA antigen is of the A/swine/Gent/1/1984-like H3N2 (Gent/84) lineage, and the third NA antigen is selected from the A(H1N1)pdm09 (pdm09) lineage or the Eurasian avian-like H1avN1 (EA) lineage. In other embodiments, the present invention relates to RNA replicon particles comprising the nucleic acid construct, an immunogenic composition, such as a vaccine, which may be used against influenza A virus infection, and comprising the replicon particles.

Abstract: The present invention relates to a method of vaccination. Specifically the invention regards to a prime-boost vaccination regimen for protecting a target animal against infection or disease caused by a virus, wherein the vaccination regimen comprises the administration to said target animal of a vaccine comprising a live attenuated form of said virus, followed by the administration to said target animal of a vaccine comprising an RP encoding one or more antigens from said virus.

Abstract: The present invention provides vectors and/or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and/or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

Abstract: The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.